201 435

Cited 5 times in

Recombinant interferon-Beta-1alpha plus ribavirin for the treatment of chronic HCV infection: a prospective, randomized, comparative pilot study

DC Field Value Language
dc.contributor.author김용수-
dc.contributor.author김자경-
dc.contributor.author안상훈-
dc.contributor.author이현웅-
dc.contributor.author전재윤-
dc.contributor.author한광협-
dc.date.accessioned2015-04-24T17:11:21Z-
dc.date.available2015-04-24T17:11:21Z-
dc.date.issued2009-
dc.identifier.issn1976-2283-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/104923-
dc.description.abstractBACKGROUND/AIMS: Interferon beta (IFN-beta) has been shown to have antiviral activity, and thus could be useful in treating viral infections. Therefore, we compared the efficacy and safety of recombinant IFN-beta (IFN-beta-1a) plus oral ribavirin versus interferon alpha (IFN-alpha) plus ribavirin therapy for the treatment of chronic hepatitis C (HCV). METHODS: Twenty treatment-naïve patients were randomized into two equal-sized treatment groups. Both IFN-beta-1a (44 microg) and IFN-alpha (3 MIU) were given subcutaneously three times a week, while ribavirin was given orally at 1,000-1,200 mg/day. Patients were treated for 24 weeks and followed for an additional 24 weeks. RESULTS: After 24 weeks of treatment, six (60%) and four patients (40%) in the IFN-beta-1a group and IFN-alpha groups, respectively, achieved viral clearance. The sustained virological response (SVR) at the end of the observation period was similar in both groups (40%). However, the baseline viral load was significantly higher (p=0.034) in the IFN-beta-1a group than in the IFN-alpha group, and there were more HCV genotype 1 patients in the IFN-beta-1a group (eight versus seven). The IFN-beta-1a group was associated with similar adverse events in terms of frequency and severity. CONCLUSIONS: The SVR rate and safety profile were similar for the combination of IFN-beta-1a and ribavirin and that of IFN-alpha and ribavirin-
dc.description.statementOfResponsibilityopen-
dc.format.extent20~25-
dc.relation.isPartOfGUT AND LIVER-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.titleRecombinant interferon-Beta-1alpha plus ribavirin for the treatment of chronic HCV infection: a prospective, randomized, comparative pilot study-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학)-
dc.contributor.googleauthorSang Hoon Ahn-
dc.contributor.googleauthorHyun Woong Lee-
dc.contributor.googleauthorYong Soo Kim-
dc.contributor.googleauthorJa Kyung Kim-
dc.contributor.googleauthorKwang-Hyub Han-
dc.contributor.googleauthorChae Yoon Chon-
dc.contributor.googleauthorYoung Myoung Moon-
dc.identifier.doi10.5009/gnl.2009.3.1.20-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA00852-
dc.contributor.localIdA02226-
dc.contributor.localIdA03292-
dc.contributor.localIdA04268-
dc.contributor.localIdA03544-
dc.contributor.localIdA00747-
dc.relation.journalcodeJ00954-
dc.identifier.eissn2005-1212-
dc.identifier.pmid20479896-
dc.subject.keywordHepatitis C-
dc.subject.keywordInterferons-
dc.subject.keywordProspective studies-
dc.subject.keywordTreatment outcome-
dc.contributor.alternativeNameKim, Yong Soo-
dc.contributor.alternativeNameKim, Ja Kyung-
dc.contributor.alternativeNameAhn, Sang Hoon-
dc.contributor.alternativeNameLee, Hyun Woong-
dc.contributor.alternativeNameChon, Chae Yoon-
dc.contributor.alternativeNameHan, Kwang Hyup-
dc.contributor.affiliatedAuthorKim, Ja Kyung-
dc.contributor.affiliatedAuthorAhn, Sang Hoon-
dc.contributor.affiliatedAuthorLee, Hyun Woong-
dc.contributor.affiliatedAuthorHan, Kwang Hyup-
dc.contributor.affiliatedAuthorChon, Chae Yoon-
dc.contributor.affiliatedAuthorKim, Yong Soo-
dc.citation.volume3-
dc.citation.number1-
dc.citation.startPage20-
dc.citation.endPage25-
dc.identifier.bibliographicCitationGUT AND LIVER, Vol.3(1) : 20-25, 2009-
dc.identifier.rimsid42578-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.